A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer

Published:2019-04 Issue:1 Volume:153 Page:135-148
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Choi Hye Joung,Heo Jin Hyung,Park Ju Yeon,Jeong Ju Yeon,Cho Hyeon Ju,Park Kyung Soon,Kim Se Hwa,Moon Yong Wha,Kim Jin Sung,An Hee Jung

Funder

Korea Health Industry Development Institute

Ministry of Health and Welfare

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference33 articles.

1. Global cancer statistics in the year 2000;Parkin;Lancet Oncol.,2001

2. Intraperitoneal chemotherapy comes of age;Cannistra;N. Engl. J. Med.,2006

3. Evolution of platinum resistance in high-grade serous ovarian cancer;Cooke;Lancet Oncol.,2011

4. Beyond chemotherapy: targeted therapies in ovarian cancer;Yap;Nat. Rev. Cancer,2009

5. The Akt/PKB pathway: molecular target for cancer drug discovery;Cheng;Oncogene,2005

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer;Medicinal Research Reviews;2024-05-20

2. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track?;Current Medicinal Chemistry;2024-04-04

3. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-03-03

4. Targeting autophagy drug discovery: Targets, indications and development trends;European Journal of Medicinal Chemistry;2024-03

5. Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles;International Journal of Molecular Sciences;2024-02-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3